翁良 博士

副研究员 博士生导师

北京大学基础医学院病理学系

Liang Weng, Ph.D.

Assistant Professor (Tenure-Track), Associate Investigator

Department of Pathology

Peking University Health Science Center

Email: wengliang@bjmu.edu.cn

教育经历 Education Background

2005 北京大学基础医学学士

 B.S. in Basic Medical Science, Peking University, China (2005)

2009 卫生部北京老年医学研究所老年医学硕士

 M.S. in Geriatrics, Beijing Institute of Geriatrics, National Health Commission, China (2009)

2013 名古屋大学病理学博士

 Ph.D. in Pathology, Nagoya University, Japan (2013)

研究经历 Professional Experience

2013 -2014名古屋大学病理系博士后

Postdoctoral Fellow, Department of Pathology, Nagoya University, Japan (2013-2014)

2014-2018 名古屋大学病理系特任助理教授

Designated Assistant Professor, Department of Pathology, Nagoya University, Japan (2014-2018)

2018-2024 中南大学湘雅医院副研究员

 Associate Investigator, Xiangya Hospital, Central South University, China (2018-2024)

2024-至今 北京大学医学部基础医学院病理学系助理教授（新体制）/副研究员

Assistant Professor (Tenure-Track), Associate Investigator, Department of Pathology, School of Basic Medical Science, Peking University Health Science Center, China (2024-present)

研究方向 Research Interests

长期致力于代谢重编程和免疫微环境重塑在疾病尤其是肿瘤进展中的研究。揭示了翻译后修饰通过代谢重编程和免疫微环境重塑参与肿瘤和心血管相关疾病进展的新机制，建立了基于免疫微环境的肺鳞癌预后诊断模型。近五年主持国家自然科学基金两项，湖南省卫健委重点课题一项，获得省部级人才计划2项。

我们的远期愿景旨在通过深入理解肿瘤生物学机制，推动肺癌诊断和治疗的进步。目前研究方向集中于肺癌的发生及免疫治疗抵抗的机制研究，主要包括以下几个方面：

1、 翻译后修饰在肺癌发生和治疗中的调控作用，

2、 肺癌亚型之间转化机制及其对治疗的影响

3、 基于数字病理和多组学探索新型肿瘤诊断标记物

Dedicated to studying metabolic reprogramming and immune microenvironment remodeling in disease progression, particularly in tumors. We have unveiled novel mechanisms by which post-translational modifications participate in the progression of cancer and cardiovascular-related diseases through metabolic reprogramming and immune microenvironment remodeling. Additionally, we have established a prognostic diagnostic model for squamous cell lung cancer based on the immune microenvironment. Over the past five years, I have led two National Natural Science Foundation of China projects, one key project from the Hunan Provincial Health Commission, and received two provincial talent programs.

Our long-term vision is to advance lung cancer diagnosis and treatment by deeply understanding the biological mechanisms of tumors. Currently, my research focuses on the mechanisms of lung cancer occurrence and resistance to immunotherapy, including:

1. The regulatory role of post-translational modifications in lung cancer occurrence and treatment

2. The mechanisms of subtype transition in lung cancer and its impact on treatment

3. The exploration of novel tumor diagnostic markers based on digital pathology and multi-omics

代表著作Selected Publications

1. Yao Lu#, Yiming Leng, Yalan Li, Jie Wang, Wei Wang , Ruilin Wang, Yuanyuan Liu, Qian Tan, Wenjing Yang, Youxiang Jiang, Jingjing Cai, Hong Yuan, Liang Weng#, Qingbo Xu#. Endothelial RIPK1 protects artery bypass graft against arteriosclerosis by regulating SMC growth. Sci Adv. 2023;9(35):eadh893. doi: 10.1126/sciadv.adh8939. (#Corresponding Author)

2. Feiyu Tang , Can Lu, Xiang He, Wei Lin, Bowen Xie, Xing Gao, Yang Peng, Desong Yang, Lunquan Sun#, Liang Weng#. E3 ligase Trim35 inhibits LSD1 demethylase activity through K63-linked ubiquitination and enhances anti-tumor immunity in NSCLC. Cell Rep. 2023;42(12):113477. (#Corresponding Author)

3. Liang Weng, Atsushi Enomoto, Hiroshi Miyoshi, Kiyofumi Takahashi, Naoya Asai, Nobuhiro Morone, Ping Jiang, Jian An, Takuya Kato, Keisuke Kuroda, Takashi Watanabe, Masato Asai, Maki Ishida-Takagishi, Yoshiki Murakumo, Hideki Nakashima, Kozo Kaibuchi, Masahide Takahashi. Regulation of cargo-selective endocytosis by dynamin 2 GTPase-activating protein girdin. EMBO J. 2014; 33:2098-112.

4. Liang Weng*#, Yi-Peng Han*, Atsushi Enomoto#, Yasuyuki Kitaura, Shushi Nagamori, Yoshikatsu Kanai, Naoya Asai, Jian An, Maki Takagishi, Masato Asai, Shinji Mii, Takashi Masuko, Yoshiharu Shimomura, Masahide Takahashi#. Negative regulation of amino acid signaling by MAPK-regulated 4F2hc/Girdin complex. PLoS Biol. 2018; 16(3):e2005090. (#Corresponding Author, * First Author)

5. Jun Lu, Yumei Duan, Pinbo Liu, Xiang He, Yiping Yang, Ran Zhang, Liang Weng#. Identification of tumour-infiltrating myeloid subsets associated with overall survival in lung squamous cell carcinoma. J Pathol. 2023;259:21-34. (#Corresponding Author)

6. Yao Lu, Haibo Tang, Peiyuan Huang, Jie Wang, Peizhi Deng, Yalan Li, Jie Zheng, Liang Weng. Assessment of causal effects of visceral adipose tissue on risk of cancers: a Mendelian randomization study. Int J Epidemiol. 2022;51:1204-1218. (#Corresponding Author)

7. Jiang He, Liyu Liu, Feiyu Tang, You Zhou, Huan Liu, Can Lu, Deyun Feng, Hong Zhu, Yitao Mao, Zhi Li, Lu Zhang, Yuemei Duan, Zhi Xiao, Musheng Zeng, Liang Weng#, Lunquan Sun#. Paradoxical effects of DNA tumor virus oncogenes on epithelium-derived tumor cell fate during tumor progression and chemotherapy response. Signal Transduct Target Ther. 2021;6:408. (#Corresponding Author)

8. Zhuan Li, Songming Chen, Xiang He, Siyuan Gong, Lunquan Sun, Liang Weng#. SLC3A2 Promotes Tumor Associated Macrophage Polarization via Metabolic Reprogramming in Lung Cancer. Cancer Sci. 2023;114:2306-2317. (#Corresponding Author)

9. Fuyang Cao, Desong Yang, Feiyu Tang, Can Lu, Xiang He, Songming Chen, Zhanghuan Yang, Siyuan Gong, Lunquan Sun, Atsushi Enomoto, Masahide Takahashi#, Liang Weng#. Girdin Promotes Tumorigenesis and Chemoresistance in Lung Adenocarcinoma by Interacting with PKM2. Cancers (Basel). 2022;14:5688. (#Corresponding Author)

10. Feiyu Tang, Fuyang Cao, Can Lu, Xiang He, Liang Weng#, Lunquan Sun#. Dvl2 facilitates the coordination of NF-κB and Wnt signaling to promote colitis-associated colorectal progression. Cancer Sci. 2022;113:565-575. (#Corresponding Author)